Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Joel Turner, Daniel Sullivan, Yun Dai, Steven Grant

Cancer Res (2016) 76 (14_Supplement): 3020.

https://doi.org/10.1158/1538-7445.AM2016-3020

Published: 15 July 2016

View article titled, Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Journal Articles

Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Hua Yang, Michael F. Emmons, Christopher Cubitt, Ken Shain, Domenico Coppola, Daniel Sullivan, Conor C. Lynch, Lori Hazlehurst, Said M. Sebti

Cancer Res (2015) 75 (15_Supplement): 2605.

https://doi.org/10.1158/1538-7445.AM2015-2605

Published: 01 August 2015

View article titled, Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Journal Articles

Abstract 4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI-101-induced cell death in myeloma

Michael Emmons, Lori Hazlehurst, Steven Escherich, Mark McLaughlin, Javier Cuevas, Daniel Sullivan

Cancer Res (2015) 75 (15_Supplement): 4439.

https://doi.org/10.1158/1538-7445.AM2015-4439

Published: 01 August 2015

View article titled, Abstract 4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI-101-induced cell death in myeloma

Journal Articles

Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer

Hatem H Soliman, Susan E Minton, Roohi Ismail-Khan, Hyo S Han, Nicholas N Vahanian, Charles J Link, Gene Kennedy, Howard Streicher, Daniel Sullivan, Scott J Antonia

Cancer Res (2015) 75 (9_Supplement): P2-15-04.

https://doi.org/10.1158/1538-7445.SABCS14-P2-15-04

Published: 01 May 2015

View article titled, Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer

Journal Articles

Abstract 812: Assessing combinations of FDA approved chemotherapy in childhood sarcoma cell lines

Diana Yu, Christopher Cubitt, Daniel Sullivan, Damon Reed

Cancer Res (2014) 74 (19_Supplement): 812.

https://doi.org/10.1158/1538-7445.AM2014-812

Published: 01 October 2014

View article titled, Abstract 812: Assessing combinations of FDA approved chemotherapy in childhood sarcoma cell lines

Journal Articles

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Rupal Ramakrishnan, Chun Huang, Hyun-Il Cho, Mark Lloyd, Joseph Johnson, Xiubao Ren, Soner Altiok, Daniel Sullivan, Jeffrey Weber, Esteban Celis, Dmitry I. Gabrilovich

Cancer Res (2012) 72 (21): 5483–5493.

https://doi.org/10.1158/0008-5472.CAN-12-2236

Published: 31 October 2012

View article titled, Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Includes: Supplementary data

Journal Articles

Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

Timothy A. Yap, Kyriakos Papadopoulos, Ivy Fearen, Christopher Carpenter, Liliana Delgado, Adekemi Taylor, David Olmos, Andre Brunetto, Matthew Tall, Shaun Decordova, Mike I. Walton, Simon P. Heaton, Michelle D. Garrett, Julia Domsch, Amita Patnaik, Daniel Sullivan, Li Yan, Johann S. de Bono, Anthony W. Tolcher

Cancer Res (2010) 70 (8_Supplement): 27.

https://doi.org/10.1158/1538-7445.AM10-27

Published: 15 April 2010

View article titled, Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

Journal Articles

Abstract #3590: Phase I pharmacodynamic study of triciribine phosphate, a small molecule inhibitor of Akt phosphorylation, in adult subjects with solid tumors containing phosphorylated Akt .

Christopher Garrett, Domenico Coppola, Robert Wenham, Christopher Cubitt, Anthony Neuger, Timothy Frost, Richard Lush, Daniel Sullivan, Jin Cheng, Said Sebti

Cancer Res (2009) 69 (9_Supplement): 3590.

Published: 01 May 2009

View article titled, Abstract #3590: Phase I pharmacodynamic study of triciribine phosphate, a small molecule inhibitor of Akt phosphorylation, in adult subjects with solid tumors containing phosphorylated Akt .

Journal Articles

Abstract #319: Intrinsic drug resistance to doxorubicin is mediated by soluble factors in multiple myeloma

Jana Dawson, Joel Turner, Elizabeth Ciaravino, Daniel Sullivan

Cancer Res (2009) 69 (9_Supplement): 319.

Published: 01 May 2009

View article titled, Abstract #319: Intrinsic drug resistance to doxorubicin is mediated by soluble factors in multiple myeloma

Journal Articles

Abstract #674: Small molecules that target the nuclear export signal of topoisomerase II alpha for the treatment of multiple myeloma

Joel Turner, Thomas Rowe, David Ostrov, Jana Dawson, Chris Cubitt, Daniel Sullivan

Cancer Res (2009) 69 (9_Supplement): 674.

Published: 01 May 2009

View article titled, Abstract #674: Small molecules that target the nuclear export signal of topoisomerase II alpha for the treatment of multiple myeloma

Journal Articles

Abstract #830: Dasatinib and cytarabine (AraC) combinations synergistically inhibit the growth of sarcoma cells

Christopher Cubitt, Jillaina Menth, Jana Dawson, Richard Lush, Daniel Sullivan

Cancer Res (2009) 69 (9_Supplement): 830.

Published: 01 May 2009

View article titled, Abstract #830: Dasatinib and cytarabine (AraC) combinations synergistically inhibit the growth of sarcoma cells

Journal Articles

Combined dasatinib and tricribine treatment synergistically inhibits the growth of sarcoma cells.

Christopher Cubitt, Jana Gump, Elissa Fielding, Jillaina Menth, Jin Cheng, Said Sebti, Daniel Sullivan

Cancer Res (2008) 68 (9_Supplement): 4038.

Published: 01 May 2008

View article titled, Combined dasatinib and tricribine treatment synergistically inhibits the growth of sarcoma cells.

Journal Articles

Toposisomerase II alpha trafficking between the nucleus and cytoplasm is controlled by phosphorylation of a casein kinase II site in the carboxy-terminal domain

Joel Turner, Jana Gump, Bin Fang, John Koomen, Daniel Sullivan

Cancer Res (2008) 68 (9_Supplement): 775.

Published: 01 May 2008

View article titled, Toposisomerase II alpha trafficking between the nucleus and cytoplasm is controlled by phosphorylation of a casein kinase II site in the carboxy-terminal domain

Journal Articles

PDGF-R alpha expression and activation in human sarcoma.

T. Christopher Windham, Gina Z. D’Amato, Elizabeth A. Keschman, Subhra Mohapatra, Audrey C. Burns, Daniel Sullivan, G. Douglas Letson, Rich Jove, W. Jack Pledger

Cancer Res (2006) 66 (8_Supplement): 1176.

Published: 15 April 2006

View article titled, PDGF-R alpha expression and activation in human sarcoma.

Journal Articles

Expanding the Use of Magnetic Resonance in the Assessment of Tumor Response to Therapy: Workshop Report

Jeffrey Evelhoch, Michael Garwood, Daniel Vigneron, Michael Knopp, Daniel Sullivan, Anne Menkens, Laurence Clarke, Guoying Liu

Cancer Res (2005) 65 (16): 7041–7044.

https://doi.org/10.1158/0008-5472.CAN-05-0674

Published: 15 August 2005

View article titled, Expanding the Use of Magnetic Resonance in the Assessment of Tumor Response to Therapy: Workshop Report

Journal Articles

Breast cancer resistance protein expression and function in multiple myeloma

Joel Turner, Rachel Karlnoski, Douglas Marchion, Elona Bicaku, Jennifer Derderian, Nikola Valkov, Jana Gump, Daniel Sullivan

Cancer Res (2004) 64 (7_Supplement): 119.

Published: 01 April 2004

View article titled, Breast cancer resistance protein expression and function in multiple myeloma

NARROW

Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Abstract 4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI-101-induced cell death in myeloma

Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer

Abstract 812: Assessing combinations of FDA approved chemotherapy in childhood sarcoma cell lines

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

Abstract #3590: Phase I pharmacodynamic study of triciribine phosphate, a small molecule inhibitor of Akt phosphorylation, in adult subjects with solid tumors containing phosphorylated Akt .

Abstract #319: Intrinsic drug resistance to doxorubicin is mediated by soluble factors in multiple myeloma

Abstract #674: Small molecules that target the nuclear export signal of topoisomerase II alpha for the treatment of multiple myeloma

Abstract #830: Dasatinib and cytarabine (AraC) combinations synergistically inhibit the growth of sarcoma cells

Combined dasatinib and tricribine treatment synergistically inhibits the growth of sarcoma cells.

Toposisomerase II alpha trafficking between the nucleus and cytoplasm is controlled by phosphorylation of a casein kinase II site in the carboxy-terminal domain

PDGF-R alpha expression and activation in human sarcoma.

Expanding the Use of Magnetic Resonance in the Assessment of Tumor Response to Therapy: Workshop Report

Breast cancer resistance protein expression and function in multiple myeloma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only